Insights and updates

Braskem studies Recurrent Money Past of R$265 million in 4Q24; Ordinary EBITDA of US$1.1 billion in 2024 (46% upper than 2023)


SÃO PAULO, Feb. 27, 2025 /PRNewswire/ — BRASKEM S.A. (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK) the most important resin manufacturer within the Americas and the arena’s important biopolymers manufacturer, items its 4Q24 Income Reduce.

4Q24 HIGHLIGHTS 

CONSOLIDATED

  • Ordinary EBITDA of US$102 million.
  • Money place of US$2.4 billion, making sure protection of debt maturities over the later 47 months.
  • Running Money Past of US$ 204 million, about R$ 1.1 billion.

The total income reduce is to be had at the Corporate’s IR site: www.braskem-ri.com.br/en

Braskem will host convention shouts to talk about its Effects Thursday, February 27 at 09:00 a.m. US ET.

Alternative data could also be acquired from the Investor Family members Segment at +55 11 3576-9531 or [email protected].

SOURCE Braskem



Source link